Live Breaking News & Updates on மைக்கேல் சேவேரினோ|Page 9

Stay updated with breaking news from மைக்கேல் சேவேரினோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RINVOQ Achieved Superiority Versus DUPIXENT® For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis


ABBVie today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 …
ABBVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 percent of dupilumab-treated patients (p=0.006). 1 Upadacitinib also showed sup ....

United States , Michael Severino , Upadacitinib Monotherapy , European Academy Of Dermatology , European Commission , Drug Administration , Exchange Commission , Abbvie Inc , Venerology Congress , Clinical Program , Eczema Area Severity Index , Worst Pruritus Numerical Rating Scale , Worst Pruritus , Eczema Area , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Medication Guide , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Moderate To Severe Atopic Dermatitis , Results From , Placebo Controlled Studies ,

RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis


RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
- Upadacitinib showed superiority versus dupilumab for all ranked secondary endpoints, including early improvements in itch and skin clearance[1]
- The Heads Up study evaluated upadacitinib (30 mg, once daily) versus dupilumab (300 mg, every other week) in adults with moderate to severe atopic dermatitis[1]
- The safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observed[1-3] ....

United States , Michael Severino , Upadacitinib Monotherapy , European Academy Of Dermatology , European Commission , Drug Administration , Exchange Commission , Abbvie Inc , Venerology Congress , Clinical Program , Eczema Area Severity Index , Worst Pruritus Numerical Rating Scale , Heads Up Results , Worst Pruritus , About Atopic , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Vie Data , Moderate To Severe Atopic Dermatitis , Results From , Placebo Controlled Studies ,